drugset / Trial / NCT04721301
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
NaSingle-groupOpen-labelTreatment
Summary
The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents.
Timeline
- Start
- 2017-01-15
- Primary completion
- 2023-03-15
- Completion
- 2023-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Maraviroc | Other / unclassified | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |